OSTX Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

OS Therapies Inc | Needs refresh | Last updated: 2026-03-29T08:34:16Z

TickerOSTX

Market Cap49.6M

Cash RunwayRunway < 6 months

Next Catalyst2027-09

Public Research Snapshot

OS Therapies Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
HER 2 Therapies	n/a	n/a	n/a	Public pipeline row
OST31	future patients	n/a	n/a	Public pipeline row
OST31-164 Expanded Access Policy	n/a	n/a	n/a	Public pipeline row
Cutting-Edge Cancer Treatment Technologies	n/a	Vaccine	n/a	Public pipeline row
OST-HER2 LM Vaccine	n/a	Vaccine	n/a	Public pipeline row
Mechanism of Action	n/a	Vaccine	n/a	Public pipeline row
Clinical Importance	n/a	Vaccine	n/a	Public pipeline row
OST-tADC Tunable Drug Conjugates	n/a	n/a	n/a	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-09	AZD2936	Low
		Data Readout	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT00308516	Phase 2	COMPLETED	66	2009-04
NCT04737187	Phase 3	COMPLETED	492	2022-07-19
NCT03768414	Phase 3	COMPLETED	452	2023-10-04
NCT04050709	Phase 1	ACTIVE_NOT_RECRUITING	16	2026-03-30
NCT05414032	Phase 2	RECRUITING	102	2027-09

Scientific Context

catalyst_type | Data Readout
asset_name | 5-Fluorouracil
clinical_stage | Phase 2
clinical_stage | Phase 2
indication | Rectal Cancer | Cancer of the Rectum | Colorectal Cancer

Want the full OSTX research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.